Published in J Nucl Med on December 01, 2012
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | NCT03181867
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
Quantitative (18)F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring. EJNMMI Res (2017) 1.37
Current use of PSMA-PET in prostate cancer management. Nat Rev Urol (2016) 1.27
¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J Nucl Med (2015) 1.21
Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging (2013) 1.13
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2014) 1.10
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res (2014) 1.08
The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol (2013) 1.04
Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging (2016) 1.03
Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men. Theranostics (2014) 1.00
Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjug Chem (2013) 0.97
Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging (2015) 0.97
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis (2016) 0.95
⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem (2014) 0.94
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics (2015) 0.94
Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem (2012) 0.93
Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med (2015) 0.91
Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen. J Nucl Med (2015) 0.91
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci (2013) 0.89
Imaging active urokinase plasminogen activator in prostate cancer. Cancer Res (2015) 0.88
(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging (2016) 0.87
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol Imaging Biol (2016) 0.87
AEG-1 promoter-mediated imaging of prostate cancer. Cancer Res (2014) 0.86
Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem (2013) 0.86
Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. J Nucl Med (2015) 0.85
Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. Clin Cancer Res (2014) 0.85
Nuclear imaging of renal tumours: a step towards improved risk stratification. Nat Rev Urol (2015) 0.84
PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci (2014) 0.84
A Bright Future for Precision Medicine: Advances in Fluorescent Chemical Probe Design and Their Clinical Application. Cell Chem Biol (2016) 0.84
Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging. Front Oncol (2016) 0.83
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. J Nucl Med (2016) 0.83
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging (2016) 0.83
(68)Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol (2016) 0.82
Heterobivalent agents targeting PSMA and integrin-αvβ3. Bioconjug Chem (2014) 0.82
Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. Eur Radiol (2015) 0.82
Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. Oncotarget (2015) 0.82
Translational Molecular Imaging of Prostate Cancer. Curr Radiol Rep (2013) 0.82
Molecular-genetic imaging of cancer. Adv Cancer Res (2014) 0.81
Evaluation of prostate-specific membrane antigen as an imaging reporter. J Nucl Med (2014) 0.80
Uptake of (18)F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies. Tomography (2015) 0.80
Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma. Clin Nucl Med (2016) 0.79
[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA). J Med Chem (2015) 0.79
Development of targeted near-infrared imaging agents for prostate cancer. Mol Cancer Ther (2014) 0.78
Biomarkers in preclinical cancer imaging. Eur J Nucl Med Mol Imaging (2015) 0.78
Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells. Int J Oncol (2014) 0.78
Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging (2013) 0.78
[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance. Bioconjug Chem (2016) 0.78
Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting. Prostate (2014) 0.78
Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.78
Synthesis and pre-clinical evaluation of a new class of high-affinity (18)F-labeled PSMA ligands for detection of prostate cancer by PET imaging. Eur J Nucl Med Mol Imaging (2016) 0.78
Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. J Nucl Med (2016) 0.78
Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine. Curr Opin Oncol (2016) 0.77
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol (2016) 0.76
Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma. Eur J Nucl Med Mol Imaging (2015) 0.75
Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA. Bioconjug Chem (2016) 0.75
PSMA PET and Radionuclide Therapy in Prostate Cancer. Semin Nucl Med (2016) 0.75
A PSMA-targeted theranostic agent for photodynamic therapy. J Photochem Photobiol B (2016) 0.75
Molecular imaging of urogenital diseases. Semin Nucl Med (2014) 0.75
Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer. Indian J Nucl Med (2017) 0.75
Molecular imaging and fusion targeted biopsy of the prostate. Clin Transl Imaging (2016) 0.75
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging (2017) 0.75
Clinical impact of PSMA-based (18)F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging (2017) 0.75
Repeatability of [(68)Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Mol Imaging Biol (2017) 0.75
Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo. Int J Oncol (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med (2006) 3.51
Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP (2008) 3.31
Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med (2007) 3.08
Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med (2007) 2.83
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 2.77
Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol (2000) 2.29
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res (2005) 1.97
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol (2007) 1.95
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
Physical models and dose factors for use in internal dose assessment. Health Phys (2003) 1.85
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
Basic anatomical and physiological data for use in radiological protection: the skeleton. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. Ann ICRP (1995) 1.52
18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis (2011) 1.50
Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol (2009) 1.49
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology (2001) 1.41
Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med (2010) 1.38
Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem (2001) 1.32
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med (2010) 1.27
Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg (2006) 1.23
Dose to the fetus from radionuclides in the bladder. Health Phys (1973) 1.22
Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc (2007) 1.22
PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med (2009) 1.22
Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem (2002) 1.14
The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res (2011) 1.12
The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging (2009) 1.12
GCPII imaging and cancer. Curr Med Chem (2012) 1.12
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem (2007) 1.08
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med (2011) 1.05
The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol (2004) 0.93
Method for estimating skeletal spongiosa volume and active marrow mass in the adult male and adult female. J Nucl Med (2007) 0.84
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem (2003) 5.34
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab (2012) 4.80
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
Plague: past, present, and future. PLoS Med (2008) 3.23
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol (2002) 3.12
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med (2006) 2.98
Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med (2008) 2.93
MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med (2009) 2.92
Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med (2006) 2.87
Autoimmune hypophysitis. Endocr Rev (2005) 2.86
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med (2011) 2.60
Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J (2007) 2.52
Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc (2010) 2.50
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol (2009) 2.20
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci (2005) 2.17
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res (2006) 2.15
HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci U S A (2009) 2.14
Modeling relationships between climate and the frequency of human plague cases in the southwestern United States, 1960-1997. Am J Trop Med Hyg (2002) 2.13
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res (2005) 2.10
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer (2006) 2.10
Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage (2003) 2.09
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol (2012) 2.07
The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci (2003) 2.06
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A (2004) 2.00
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
Early-phase transmission of Yersinia pestis by unblocked fleas as a mechanism explaining rapidly spreading plague epizootics. Proc Natl Acad Sci U S A (2006) 1.99
High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging (2005) 1.97
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Climate change effects on plague and tularemia in the United States. Vector Borne Zoonotic Dis (2007) 1.92
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov (2005) 1.89
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer (2012) 1.87
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol (2011) 1.82
Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med (2010) 1.81
Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol (2009) 1.81
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med (2004) 1.81
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (2011) 1.80
Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology (2009) 1.80
A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett (2002) 1.79
Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem (2008) 1.79
Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology (2003) 1.77
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging (2008) 1.76
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Classic flea-borne transmission does not drive plague epizootics in prairie dogs. Proc Natl Acad Sci U S A (2006) 1.75
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med (2007) 1.73
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer (2008) 1.73